Gouty Arthritis (Gout) Pipeline Therapeutics Research 2017 Gouty Arthritis (Gout) Pipeline Review H1 2017

Gouty Arthritis (Gout) Pipeline Review H1 2017 report provides comprehensive information on the therapeutics under development for Gouty Arthritis (Gout), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. Additionally, the report provides an overview of key players involved in therapeutic development for Gouty Arthritis (Gout) and features dormant and discontinued projects. Gout is a type of arthritis where swelling and severe pain develops in joints, especially at the base of the big toe. Gout occurs when uric acid builds up in blood and causes inflammation in the joints. Symptoms include sudden onset of joint pain, joint swelling, heat in the affected area and joint redness. Risk factors include obesity, high alcohol intake, injury to a joint, long-standing kidney disease and high intake of foods rich in purines. Inquire for Complete PDF Report @ http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=1020042 Description of Report: Gouty Arthritis (Gout) Pipeline Review H1 2017 report reviews therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 11, 2, 16, 2 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecule, respectively. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive. Gouty Arthritis (Gout) Key Companies Analysed: Allena Pharmaceuticals Inc, AstraZeneca Plc, C&C Research Laboratories, Cell Medica Ltd, CymaBay Therapeutics Inc, Genentech Inc, Immune Response BioPharma Inc, Jiangsu Hengrui Medicine Co Ltd, Monosol Rx LLC, Opsona Therapeutics Ltd, Polaris Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, Swedish Orphan Biovitrum AB, Teijin Pharma Ltd, Wellstat Therapeutics Corp, XL-protein GmbH . Get Discount On Report @ http://www.reportsnreports.com/contacts/discount.aspx?name=1020042 . (This report is available at upto 25% Discount till June 02nd 2017.) Gouty Arthritis Drug Profile Discussed: ALLN-346, anakinra, APP-112, AQB-565, arhalofenate, colchicine, dapansutrile, diacerein, diacerein CR, DLX-2323, DLX-2681, febuxostat, HSA-Uricase, IR- 888, Monoclonal Antibody to Inhibit S100A9 Protein for Autoimmune Disorders, Chronic Inflammation, Neurodegenerative Diseases and Respiratory Infections, ND-2110, ND-2158, ND-346, pegadricase, R-191, Recombinant Enzyme for Gout and Tumor Lysis Syndrome, REV-002, RLBN-1001, SHR-4640, Small Molecule to Inhibit Xanthine Oxidase for Gout and Hyperuricemia, Small Molecules for Gout, Small Molecules to Inhibit GLUT9 for Gout, Small Molecules to Inhibit Interleukin 1 Beta for Muckle-Wells Syndrome, Neonatal Onset Multisystem Inflammatory Disease and Gouty Arthritis, TMX-049, URC-102, uriSHELS, VCB-201, verinurad, WT-2107, XEN-102, XL-400